Rhumbline Advisers increased its holdings in shares of Haemonetics Co. (NYSE:HAE) by 0.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,822 shares of the medical instruments supplier’s stock after purchasing an additional 224 shares during the period. Rhumbline Advisers’ holdings in Haemonetics were worth $13,981,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Financial Gravity Companies Inc. bought a new stake in Haemonetics in the 4th quarter valued at approximately $41,000. We Are One Seven LLC bought a new stake in shares of Haemonetics during the 4th quarter worth approximately $51,000. Quadrant Capital Group LLC raised its stake in shares of Haemonetics by 708.8% during the 1st quarter. Quadrant Capital Group LLC now owns 647 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 567 shares in the last quarter. Ellis Investment Partners LLC bought a new stake in shares of Haemonetics during the 1st quarter worth approximately $79,000. Finally, Hanseatic Management Services Inc. raised its stake in shares of Haemonetics by 8,500.0% during the 4th quarter. Hanseatic Management Services Inc. now owns 1,462 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 1,445 shares in the last quarter. Institutional investors and hedge funds own 98.31% of the company’s stock.

HAE stock opened at $99.93 on Thursday. The company has a current ratio of 2.44, a quick ratio of 1.62 and a debt-to-equity ratio of 0.48. The company has a market cap of $4.82 billion, a P/E ratio of 41.81, a price-to-earnings-growth ratio of 2.41 and a beta of 0.85. Haemonetics Co. has a 1-year low of $80.24 and a 1-year high of $117.56.

Haemonetics (NYSE:HAE) last posted its earnings results on Tuesday, May 7th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.06. The business had revenue of $249.30 million for the quarter, compared to analyst estimates of $250.62 million. Haemonetics had a return on equity of 18.88% and a net margin of 5.69%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.43 EPS. Equities analysts forecast that Haemonetics Co. will post 2.9 EPS for the current year.

A number of equities research analysts have recently issued reports on the company. TheStreet upgraded Haemonetics from a “c+” rating to a “b-” rating in a research note on Tuesday, May 7th. Zacks Investment Research cut Haemonetics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. Barrington Research reiterated an “outperform” rating and set a $116.00 price objective (up previously from $112.00) on shares of Haemonetics in a research note on Wednesday, May 8th. Raymond James upgraded Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 price objective on the stock in a research note on Tuesday. Finally, ValuEngine lowered Haemonetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 5th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $118.60.

In other Haemonetics news, CEO Christopher Simon sold 57,587 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $94.51, for a total value of $5,442,547.37. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Ronald G. Gelbman sold 8,196 shares of the company’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $86.52, for a total value of $709,117.92. The disclosure for this sale can be found here. Insiders have sold a total of 69,496 shares of company stock worth $6,479,049 over the last three months. 1.04% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Haemonetics Co. (HAE) Stake Boosted by Rhumbline Advisers” was posted by Marea Informative and is the property of of Marea Informative. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.mareainformativa.com/news/2019/05/16/haemonetics-co-hae-stake-boosted-by-rhumbline-advisers.html.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

See Also: P/E Growth (PEG)

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.